Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission

References

• Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182–205
   PubMed Web of Science ®Google Scholar
• Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives: a possible etiologic fator. Ann Intern Med 1986; 105: 883–5
   PubMed Web of Science ®Google Scholar
• Katz KD, Hollander D, Vadheim C, McElrie C, Delahunty T, Dadufalza UD, et al. Intestinal permeability in patients with Crohn's disease and their relatives. Gastroenterology 1989; 97: 927–31
   PubMed Web of Science ®Google Scholar
• Hollander D. Crohn's disease, TNF-α, and the leaky gut. The chicken or the egg?. Am J Gastroenterol 2002; 97: 1867–8
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Ghoos Y, Van Trappen E, Eyssen H. Ileal dysfunction and bacterial overgrowth in patients with Crohn's disease. Eur J Clin Invest 1981; 11: 199–206
   PubMed Web of Science ®Google Scholar
• Bengmark S. Ecological control of the gastrointestinal tract. The role of probiota flora. Gut 1998; 42: 2–7
   PubMed Web of Science ®Google Scholar
• Spirt MJ. Antibiotics in inflammatory bowel disease: new choices for an old disease. Am J Gastroenterol 1994; 89: 974–8
   PubMed Web of Science ®Google Scholar
• Chiodini RJ. Antimicrobial agents and Crohn's disease: do they have a therapeutic role?. Ital J Gastroenterol Hepatol 1998; 30: 593–8
   PubMed Web of Science ®Google Scholar
• Bjarnason I, MacPherson AJ, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566–81
   PubMed Web of Science ®Google Scholar
• Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clin Sci 1992; 82: 471–88
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976; 70: 439–44
   PubMed Web of Science ®Google Scholar
• Gasche C, Scholmerich J, Brinskov J, D'Haens G, Hanauer SB, Irvine EJ. A simple classification of Crohn's disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8–15
   PubMed Web of Science ®Google Scholar
• Wyatt J, Volgelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and prediction of relapse in Crohn's disease. Lancet 1993; 341: 1437–9
   PubMed Web of Science ®Google Scholar
• D'Inca R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, et al. Intestinal permeability test as a predictor of clinical in Crohn's disease. Am J Gastroenterol 1999; 94: 2956–60
   PubMed Web of Science ®Google Scholar
• Secondulfo M, Iafusco D, Canatu R, deMagistris L, Sapone A, Generoso M, et al. Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. Dig Liver Dis 2004; 36: 35–45
   PubMedGoogle Scholar
• Harper PH, Lee EC, Kettlewell MG, Bennett MK, Jewell DP. Role of the fecal stream in the maintenance of Crohn's colitis. Gut 1985; 26: 279–84
   PubMed Web of Science ®Google Scholar
• D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeers P. early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262–7
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603–6
   PubMed Web of Science ®Google Scholar
• Cartun RW, Van Kruiningen HJ, Pedersen CA, Bermen MM. An immunocytochemical search for infectious agents in Crohn's disease. Mod Pathol 1993; 6: 212–9
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosa flora in inflammatory bowel disease. Gastroenterology 2002; 122: 44–54
   PubMed Web of Science ®Google Scholar
• Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 1620–33
   PubMed Web of Science ®Google Scholar
• Clancy R. Immunobiotics and the probiotic evolution. FEMS Immunol Med Microbiol 2003; 38: 9–12
   PubMed Web of Science ®Google Scholar
• Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol 2006; 12: 5941–50
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863–9
   PubMed Web of Science ®Google Scholar
• Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52: 988–97
   PubMed Web of Science ®Google Scholar
• Lammers KM, Helwig U, Swennen E, Rizzello F, Venturi A, Caramelli E, et al. Effect of probiotic strains on interleukin 8 production by HT29/19a cells. Am J Gastroenterol 2002; 97: 1182–6
   PubMed Web of Science ®Google Scholar
• Blehaut H, Massot J, Elmer GW, Levy RH. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 1989; 10: 353–64
   PubMed Web of Science ®Google Scholar
• Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, Rampal P, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 2006; 131: 1812–25
   PubMed Web of Science ®Google Scholar
• Buts J-P, De Keyser N, Marandi N, Hermans D, Sokal EM, Chae YH, et al. Saccharomyces boulardii upgrades cellular adaptation after enterectomy in rats. Gut 1999; 45: 89–96
   PubMed Web of Science ®Google Scholar
• Buts J-P, De Keyser N. Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 2006; 51: 1485–92
   PubMed Web of Science ®Google Scholar
• Ricci G, Stabellini G, Bersani G, Marangoni G, Fabbri P, Gentili G, et al. Ornithine decarboxylase in colonic mucosa from patients with moderate or severe Crohn's disease and ulcerative colitis. Eur J Gastroenterol Hepatol 1999; 11: 903–4
   PubMed Web of Science ®Google Scholar
• Allgayer H, Roisch U, Zehnter E, Ziegenhagen DJ, Dienes HP, Kruis W. Colonic ornithine decarboxylase in inflammatory bowel disease: ileorectal activity gradient, guanosine triphosphate stimulation, and association with epithelial regeneration but not the degree of inflammation and clinical features. Dig Dis Sci 2007; 52: 25–30
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Van Wijngaerden E, Verwaert C, Peetermans WE. Saccharomyces fungemia complicating S. boulardii treatment in a non-immunocompromised host. Intensive Care Med 2000; 26: 825
   PubMed Web of Science ®Google Scholar
• Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea: a pilot study. Z Gastroenterol 1993; 31: 129–34
   PubMed Web of Science ®Google Scholar
• Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45: 1462–4
   PubMed Web of Science ®Google Scholar
• Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG hepful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000; 31: 453–7
   PubMed Web of Science ®Google Scholar